Previous Close | 0.0900 |
Open | 0.0900 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 30.00 |
Expire Date | 2024-10-18 |
Day's Range | 0.0900 - 0.1000 |
Contract Range | N/A |
Volume | |
Open Interest | 743 |
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
DUBLIN, August 29, 2024--Prothena today announced that members of its senior management team will participate in two upcoming investor conferences in September 2024.
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.